Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neal Shore

Showing results (91-100 of 191) with videos related to

Pageof 20
Sort By:
Cancer|June 19, 2009
Key concerns about the current state of bladder cancer: a position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic OncologyYair Lotan, Ashish M Kamat, Michael P Porter, et al.
World Journal of Urology|February 24, 2020
Prospective evaluation of fexapotide triflutate injection treatment of Grade Group 1 prostate cancer: 4-year resultsNeal Shore, Steven A Kaplan, Ronald Tutrone, et al.
The Journal of Urology|May 7, 2018
Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with AntiandrogensE David Crawford, Paul F Schellhammer, David G McLeod, et al.
The Journal of Urology|July 27, 2011
A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancerE David Crawford, Bertrand Tombal, Kurt Miller, et al.
European Urology|September 22, 2018
A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial BiopsyJames McKiernan, Michael J Donovan, Eric Margolis, et al.
European Journal of Cancer (Oxford, England : 1990)|April 12, 2026
Efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trialBertrand Tombal, Maha Hussain, Fred Saad, et al.
Science Translational Medicine|July 21, 2012
Continuous intravesical lidocaine treatment for interstitial cystitis/bladder pain syndrome: safety and efficacy of a new drug delivery deviceJ Curtis Nickel, Pankaj Jain, Neal Shore, et al.
Lancet (London, England)|March 1, 2011
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyKarim Fizazi, Michael Carducci, Matthew Smith, et al.
European Urology|December 3, 2014
Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate CancerKarim Fizazi, Christophe Massard, Matthew Smith, et al.
World Journal of Urology|April 4, 2019
A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patientsNeal Shore, Ivan Mincik, Mark DeGuenther, et al.
Pageof 20

Showing results (91-100 of 191) with videos related to

Sort By:
Pageof 20
Cancer|June 19, 2009
Key concerns about the current state of bladder cancer: a position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic OncologyYair Lotan, Ashish M Kamat, Michael P Porter, et al.
World Journal of Urology|February 24, 2020
Prospective evaluation of fexapotide triflutate injection treatment of Grade Group 1 prostate cancer: 4-year resultsNeal Shore, Steven A Kaplan, Ronald Tutrone, et al.
The Journal of Urology|May 7, 2018
Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with AntiandrogensE David Crawford, Paul F Schellhammer, David G McLeod, et al.
The Journal of Urology|July 27, 2011
A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancerE David Crawford, Bertrand Tombal, Kurt Miller, et al.
European Urology|September 22, 2018
A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial BiopsyJames McKiernan, Michael J Donovan, Eric Margolis, et al.
European Journal of Cancer (Oxford, England : 1990)|April 12, 2026
Efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trialBertrand Tombal, Maha Hussain, Fred Saad, et al.
Science Translational Medicine|July 21, 2012
Continuous intravesical lidocaine treatment for interstitial cystitis/bladder pain syndrome: safety and efficacy of a new drug delivery deviceJ Curtis Nickel, Pankaj Jain, Neal Shore, et al.
Lancet (London, England)|March 1, 2011
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyKarim Fizazi, Michael Carducci, Matthew Smith, et al.
European Urology|December 3, 2014
Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate CancerKarim Fizazi, Christophe Massard, Matthew Smith, et al.
World Journal of Urology|April 4, 2019
A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patientsNeal Shore, Ivan Mincik, Mark DeGuenther, et al.
Pageof 20